Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- 1 December 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (16), 1691-1699
- https://doi.org/10.1016/s1470-2045(15)00362-9
Abstract
No abstract availableFunding Information
- Bayer HealthCare
- Project Management
This publication has 32 references indexed in Scilit:
- Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemiaBlood Cancer Journal, 2014
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesLeukemia, 2012
- Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with SorafenibTransplantation and Cellular Therapy, 2011
- Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemiaLeukemia & Lymphoma, 2011
- A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: Evidence of efficacy continues to mountLeukemia Research, 2010
- Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial RemodelingCirculation, 2008
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous LeukemiaJNCI Journal of the National Cancer Institute, 2008
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathwayLeukemia, 2008
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- BAY 43-9006 Inhibition of Oncogenic RET MutantsJNCI Journal of the National Cancer Institute, 2006